Shandong Xinbo Pharmaceutical Research Co., Ltd. is a scientific research service-oriented enterprise integrating pharmacodynamics research, toxicology research, drug analysis and testing services, animal pathology testing, and medical device evaluation services. It is a high-tech enterprise, Shandong Enterprise Technology Center, and Shandong Gazelle Enterprise.



The company is located in the Beijing Tianjin Hebei Shandong economic zone, and has established a test base in Linyi Economic Development Zone, Dezhou City, known as "Jiuda Tianqu" and "Shenjing Portal". At present, more than 16000 square meters of pharmacology and toxicology research laboratories in line with international standards have been built, and more than 800 advanced instruments and equipment at home and abroad have been equipped. Among them, the toxicology research laboratory can carry out nine studies, including single dose toxicity test, repeated dose toxicity test, safety pharmacology test, reproductive toxicity test, genetic toxicity test, local toxicity test, immunogenicity test, toxicokinetics test and carcinogenesis test, according to the GLP standards of NMPA and FDA.



The company is based on providing high-quality commissioned research services for new drugs and medical research and development institutions. Since its establishment in 2010, it has provided more than 10000 services for more than 540 pharmaceutical companies, new drug research and development institutions and scientific research institutes at home and abroad. In accordance with the requirements of domestic and international laws and regulations, we have completed the pre clinical evaluation services for nearly 400 innovative drugs, including small molecule drugs, biomacromolecule drugs, new preventive and therapeutic vaccines, and traditional Chinese medicine/natural drugs, helped R&D units obtain more than 50 clinical approval documents for new drugs, and especially accumulated rich experience in the evaluation of therapeutic vaccines, cell and gene therapy drugs that have developed rapidly in recent years. The evaluation of nearly 4000 varieties of generic drugs was completed.



In addition, the company has constantly innovated its practices and broken through barriers, improved and explored the difficult administration technology for young animals, continuous intravenous administration technology, tracheal administration technology and other fields, and has successfully applied them to safety evaluation. The company also pays attention to the demand for innovative development of the global pharmaceutical industry. Based on the key link of innovative drug research and development, and relying on the experience accumulated in serving the domestic and foreign pharmaceutical industry, the company provides the global pharmaceutical industry with comprehensive pre clinical research and development services for new drugs.